OPTI Gsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
OPTI G develops specialized equipment for interventional cardiologists, including an optical diagnostic guidewire for accurately assessing coronary artery lesions. The company received support through the AlfaBRIdge project, implemented by the National Centre for Research and Development with the participation of the Medi Ventures investment fund.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2022-12-22. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 15, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $37,411$37,411 | OIC Poland Fundacja Akademii Wsei | |
| Dec 20, 2022 | Aid for SME access to finance — aid for start-ups | $168.7K$168,686 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 35 | $472.72 | 25.9259% | |
Krzysztof Jan Nazar (35) | 62 | $837.39 | 45.9259% |
Łukasz Wasyluk (50) | 15 | $202.59 | 11.1111% |
Damian Ziarkiewicz (45) | 15 | $202.59 | 11.1111% |
Others | 8 | $108.05 | 5.926% |
The articles of association require board approval for share transfers.
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | ||
| Quantum Innovationssp. z o.o. | $167,489.61 | quantuminnovations.pl | ||
| SatroecgS.A. | $117,301.57 | satroecg.pl | ||
| Innovations for Heart and Vesselssp. z o.o. | $77,004.75 | i4hv.com | ||
| Digital Pathology Teamsp. z o.o. | $64,552.91 | digitalpathologyteam.com | ||
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | ||
| SimplicardiacS.A. | $28,951.71 | simplicardiac.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| EFMS.A. | $8,156.49 | engineers4medicine.com | ||
| IncellvuS.A. | $6,985.93 | incellvu.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-01-25 | Share capital change (5,000.00 PLN → 6,750.00 PLN) | |
| 2023-01-18 | Address change (Ul. Modlińska 310, 03-152, Warszawa → Ul. Milenijna 43/2, 03-130, Warszawa) | |
| 2022-12-13 | Entered in the register |
FAQ
Last updated: 2026-04-18